Can a Brain Tumour be Treated with Radiotherapy? 

Radiotherapy is a primary treatment modality used in the United Kingdom to manage both benign and malignant brain tumours by using high-energy radiation beams to destroy abnormal cells. This treatment works by damaging the DNA of the tumour cells, which prevents them from growing and multiplying, while multidisciplinary teams work to minimise the impact on the surrounding healthy brain tissue. In the UK, radiotherapy may be used as a standalone treatment, following surgery to eliminate remaining cells, or in combination with chemotherapy for high-grade tumours. By adhering to evidence-based protocols established by the NHS and NICE, clinical teams ensure that radiation delivery is highly precise and tailored to the specific biology of the tumour. This article explores the various types of radiotherapy available, the clinical process of planning and delivery, and the integrated supportive care provided within the UK healthcare system. 

What We’ll Discuss in This Article 

• The biological mechanism of how radiation manages brain tumour growth. 

• Different types of delivery, including External Beam and Stereotactic Radiosurgery. 

• The role of radiotherapy in post-surgical care and for inoperable tumours. 

• The clinical planning process involving bespoke masks and scanning. 

• Managing common side effects and the importance of long-term follow-up. 

• The availability of advanced options like Proton Beam Therapy in the UK. 

The Biological Mechanism of Radiotherapy 

Radiotherapy treats brain tumours by delivering precisely controlled doses of ionising radiation that cause irreversible damage to the genetic material of rapidly dividing cells. Because tumour cells typically divide more frequently and are less efficient at repairing DNA damage than healthy cells, the radiation effectively stops the mass from expanding. The NHS states that radiotherapy uses controlled doses of high-energy radiation to kill cancer cells or stop them from multiplying. 

In the United Kingdom, the dose is usually delivered over a series of daily sessions known as “fractions” over several weeks. This fractional approach allows healthy brain cells a period of recovery between treatments, reducing the risk of long-term neurological complications. Clinical teams use this method to balance the total destructive dose required for the tumour with the biological tolerance of the sensitive structures nearby, such as the optic nerves or the brainstem. This careful calculation is a cornerstone of neuro-oncology care, ensuring that the management is as effective as possible while prioritising the patient’s functional independence. 

Types of Radiotherapy Delivery in the UK 

There are several methods of delivering radiotherapy in the United Kingdom, each chosen based on the size, type, and location of the brain tumour. External Beam Radiotherapy (EBRT) is the most common form, where a machine called a linear accelerator rotates around the patient to deliver radiation from multiple angles. For smaller or well-defined tumours, specialists may use Stereotactic Radiosurgery (SRS) or Stereotactic Radiotherapy (SRT), which provide a highly concentrated dose to a very specific target. 

Radiotherapy Type	Method of Delivery	Common Clinical Use
External Beam (EBRT)	Standard daily fractions.	Post-operative gliomas; diffuse tumours.
Stereotactic (SRS)	Single high-dose session.	Acoustic neuromas; small metastases.
Stereotactic (SRT)	Small number of high-dose sessions.	Benign tumours near sensitive structures.
Proton Beam Therapy	Use of protons instead of X-rays.	Specific paediatric or skull-base tumours.

NICE clinical guidelines for brain tumours indicate that stereotactic techniques should be considered for patients with limited brain metastases or specific benign tumours to preserve healthy tissue. This precision allows UK clinicians to treat tumours that might be inoperable due to their location deep within the brain. By using these advanced delivery systems, the NHS provides a range of options that can be customised to the patient’s specific diagnostic profile. 

The Role of Radiotherapy in Integrated Care 

Radiotherapy plays a vital role in the integrated care pathway in the UK, often serving as a complementary treatment following neurosurgery to address any microscopic tumour cells left behind. This “adjuvant” therapy is essential for high-grade tumours where the borders are not clearly defined, helping to reduce the risk of the tumour returning in the future. In cases where surgery is deemed too risky due to the tumour’s location, radiotherapy may be used as the primary management tool to control the growth. 

The clinical objectives of radiotherapy include: 

• Tumour Control: Stopping or slowing the growth of malignant or benign masses. 

• Symptom Relief: Shrinking a tumour to reduce pressure and alleviate headaches or seizures. 

• Recurrence Prevention: Destroying residual cells after a surgical resection. 

• Management of Metastases: Treating tumours that have spread to the brain from other organs. 

The GOV.UK health pages provide clinical profiles indicating that for many high-grade gliomas, radiotherapy is combined with chemotherapy to enhance the overall effectiveness of the treatment. This coordinated approach is managed by a multidisciplinary team to ensure that the timing of each treatment phase is optimal. By integrating radiation into the wider oncology strategy, the UK healthcare system provides a robust framework for managing complex neurological conditions. 

Planning and Precision: The Patient Journey 

The process of receiving radiotherapy in the United Kingdom involves a detailed planning phase to ensure that the radiation is delivered with millimetre precision. This begins with a “planning appointment” where a bespoke plastic mask is created for the patient. This mask is used during every treatment session to ensure the head remains in the exact same position, preventing the radiation beams from hitting healthy parts of the brain. 

The planning pathway involves: 

• Mask Construction: Creating a personalised mould of the patient’s face and head. 

• Planning Scans: Performing CT or MRI scans while the patient is wearing the mask. 

• Dosimetry: Specialist physicists calculating the exact angles and doses of the radiation beams. 

• Verification: Checking the accuracy of the plan before the first treatment session begins. 

During the actual treatment, which usually lasts only a few minutes, the patient must lie still while the machine moves around them. The procedure is entirely painless, and the patient is monitored via intercom and cameras by radiographers in a nearby room. In the UK, this meticulous preparation is standard across all oncology centres, reflecting a commitment to safety and diagnostic accuracy. 

Managing Side Effects and Supportive Care 

While radiotherapy is targeted, it can cause side effects as the brain and surrounding tissues react to the treatment. In the United Kingdom, specialist nurses and oncologists provide a range of supportive care options to help patients manage these effects, which are usually categorised as early or late-term. 

Common early side effects include: 

• Fatigue: A significant sense of tiredness that often develops as the treatment progresses. 

• Hair Loss: Typically occurring only in the area where the radiation enters the head. 

• Skin Irritation: Redness or sensitivity on the scalp, similar to mild sunburn. 

• Brain Swelling: Temporary inflammation that may increase headaches or nausea. 

To manage brain swelling, UK clinicians often prescribe steroid medication, such as dexamethasone, which is tapered down once the treatment is complete. Long-term side effects are rarer but can include changes in memory or cognitive function, which are monitored through the NHS follow-up pathway. This integrated support system ensures that patients are not only treated for the tumour but are also supported through the physical and emotional challenges of the therapy itself. 

Proton Beam Therapy in the UK 

Proton Beam Therapy is an advanced form of radiotherapy available at specific specialist centres in the United Kingdom, such as those in Manchester and London. Unlike traditional radiotherapy which uses X-rays, this technology uses a beam of protons that can be programmed to stop at a specific depth. This “Bragg peak” effect means that almost no radiation travels beyond the tumour, significantly reducing the dose to healthy tissues behind the mass. 

This technology is particularly valuable in the UK for: 

• Paediatric Cases: Reducing the long-term impact of radiation on a child’s developing brain. 

• Base of Skull Tumours: Where tumours are located extremely close to critical nerves and vessels. 

• Re-treatment: When a patient has already received the maximum dose of traditional radiation. 

Because it is a highly specialised resource, the NHS has strict criteria for which patients are eligible for Proton Beam Therapy. A national panel of experts reviews cases to ensure that this technology is used where it provides the greatest clinical benefit over standard radiotherapy. This ensures that UK patients have access to world-class technology when their specific diagnosis necessitates a more refined approach to radiation delivery. 

Conclusion 

Radiotherapy is a highly effective and precise treatment used in the UK to manage various brain tumours by damaging the DNA of abnormal cells. Whether delivered through standard external beams or advanced stereotactic methods, the goal is to control the growth while protecting neurological function. The planning process involving bespoke masks and specialist dosimetry ensures a high standard of safety and accuracy across the NHS. While side effects like fatigue and hair loss are common, integrated supportive care is provided to manage the patient’s wellbeing throughout the clinical journey. If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot (E-E-A-T) 

This article provides medically factual health education regarding radiotherapy for brain tumours, strictly aligned with NHS and NICE clinical guidelines. The content is developed by a professional medical writing team and reviewed by Dr. Rebecca Fernandez, a UK-trained physician with extensive experience in general surgery, cardiology, and emergency medicine. All information follows current UK public health protocols to ensure clinical accuracy and patient safety.